If you are wondering whether Novartis is priced attractively right now or if the recent run has already baked in the upside, this article walks through what the current share price might be implying.

After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its ...

Novartis presents key market opportunities through its focus on digital transformation, innovation programs, and strategic tech initiatives. It leverages partnerships, product launches, investments, ...

Novartis is a large drugmaker with a wide-ranging portfolio. Like all drugmakers, it faces the challenge of patent expirations. Still, the company's pipeline looks likely to support ongoing growth.

ROME, Georgia, Feb 19 (Reuters) - U.S. President Donald Trump said he met Vas Narasimhan, the chief executive officer of Swiss drugmaker Novartis (NOVN.S), opens new tab, at the White House on ...

Novartis AG (NYSE:NVS) is one of the best immunotherapy stocks to buy according to hedge funds. Novartis AG (NYSE:NVS) announced on February 13 final results from the Phase III ALIGN study, stating ...

The primary endpoint was met for the three most prevalent types of CIndU, achieving significantly higher complete response rates versus placebo at Week 121. The most common types include: Minor skin ...

Unnatural Products announced on Wednesday a research and licensing deal worth up to $1.8B with Novartis (NVS) to develop a class of orally delivered peptide therapies potentially targeting ...

Feb 18 (Reuters) - Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis (NOVN.S), opens new tab to develop macrocyclic peptide-based therapies for a cardiovascular ...

The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies.